Related Experiment Video
Updated: Mar 18, 2026
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study
Emanuel Citgez1, Job van der Palen2, Kirsten Koehorst-Ter Huurne3
1Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Research Methodology, Measurement, and Data analysis, University of Twente, Enschede, The Netherlands.
Insights
Statins did not improve survival or reduce hospitalizations for COPD exacerbations or pneumonia in a study of 795 patients. Further research is needed to clarify statin benefits in COPD management.
Area of Science:
- Pulmonary Medicine
- Cardiovascular Medicine
- Pharmacology
Background:
- Chronic inflammation and cardiovascular comorbidity significantly impact COPD morbidity and mortality.
- Statins are considered for adjunct therapy in COPD, but their additional benefits remain debated.
- Investigating statin use and clinical outcomes in COPD patients is crucial.
Purpose of the Study:
- To assess the association between statin use and clinical outcomes in a well-defined COPD cohort.
- To evaluate the impact of statins on 3-year survival, AECOPD hospitalizations, and CAP incidence.
- To address potential biases, including immortal time bias, in the analysis.
Main Methods:
- A cohort of 795 patients from the COMIC study was divided into statin users and non-users.
- Statin use was defined as continuous use for at least 90 days post-inclusion.
- Outcomes included 3-year all-cause mortality, time to first AECOPD hospitalization, and time to first CAP, with sensitivity analysis performed.
Main Results:
- Initial analysis suggested improved overall survival with statin use (aHR 0.70), but this association vanished in sensitivity analysis.
- Statin use showed no significant association with time to first AECOPD hospitalization (cHR 0.95).
- Statin use was not linked to a reduced time to first community-acquired pneumonia (cHR 1.1).
Conclusions:
- Statin use in the COMIC COPD cohort was not associated with reduced all-cause mortality.
- Statins did not demonstrate a significant effect on decreasing hospitalizations for AECOPD.
- No association was found between statin use and a reduced risk of community-acquired pneumonia in COPD patients.
Background:
Both chronic inflammation and cardiovascular comorbidity play an important role in the morbidity and mortality of patients with chronic obstructive pulmonary disease (COPD). Statins could be a potential adjunct therapy. The additional effects of statins in COPD are, however, still under discussion. The aim of this study is to further investigate the association of statin use with clinical outcomes in a well-described COPD cohort.
Methods:
795 patients of the Cohort of Mortality and Inflammation in COPD (COMIC) study were divided into statin users or not. Statin use was defined as having a statin for at least 90 consecutive days after inclusion. Outcome parameters were 3-year survival, based on all-cause mortality, time until first hospitalisation for an acute exacerbation of COPD (AECOPD) and time until first community-acquired pneumonia (CAP). A sensitivity analysis was performed without patients who started a statin 3 months or more after inclusion to exclude immortal time bias.
Results:
Statin use resulted in a better overall survival (corrected HR 0.70 (95% CI 0.51 to 0.96) in multivariate analysis), but in the sensitivity analysis this association disappeared. Statin use was not associated with time until first hospitalisation for an AECOPD (cHR 0.95, 95% CI 0.74 to 1.22) or time until first CAP (cHR 1.1, 95% CI 0.83 to 1.47).
Conclusions:
In the COMIC study, statin use is not associated with a reduced risk of all-cause mortality, time until first hospitalisation for an AECOPD or time until first CAP in patients with COPD.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:20Chronic Obstructive Pulmonary Disease-I: Introduction